The clinical study of the activated self-lymphocytes introduction therapy using a self-tumor (tissue) and a dendritic cells for a relapse and a advanced cancer.
Not Applicable
- Conditions
- Relapse and advanced cancer
- Registration Number
- JPRN-UMIN000006276
- Lead Sponsor
- Tomishiro Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) The patients with autoimmune disease 2) The patients with complications having poor control. (An infection, diabetes, hypertension, ischemic heart disease, cerebral infraction, etc.). 3) The patients egnancy nursing mother and the pregnant likelihood(possibility). 4) The patients history of the drug allergy. 5) Other, the patients is judged inadequate by research contact person.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Establishment of the procedure, verification of tolerability and safety of "the activated self-lymphocytes introduction therapy using a self-tumor (tissue) and dendritic cells.
- Secondary Outcome Measures
Name Time Method QOL, A cytoreductive effect and a prognosis prolongation effect.